Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ogalvibart (C-135-LS), a humanized anti-SARS-CoV-2 IgG1 type monoclonal antibody, specifically targets and binds to the spike (S) glycoprotein receptor-binding domain (RBD) of the SARS-CoV-2 virus. When combined with C144LS in a 1:1 ratio, Ogalvibart demonstrates significant preventive activity and effectively prevents the progression of COVID-19 in a rhesus monkey disease model [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Ogalvibart (C-135-LS), a humanized anti-SARS-CoV-2 IgG1 type monoclonal antibody, specifically targets and binds to the spike (S) glycoprotein receptor-binding domain (RBD) of the SARS-CoV-2 virus. When combined with C144LS in a 1:1 ratio, Ogalvibart demonstrates significant preventive activity and effectively prevents the progression of COVID-19 in a rhesus monkey disease model [1]. |
Molecular Weight | N/A |
CAS No. | 2599039-60-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ogalvibart 2599039-60-6 inhibitor inhibit